<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04468568</url>
  </required_header>
  <id_info>
    <org_study_id>00607219.4.0030.0099</org_study_id>
    <nct_id>NCT04468568</nct_id>
  </id_info>
  <brief_title>In Utero Repair of Myelomeningocele: Atosiban Versus Terbutaline</brief_title>
  <official_title>Assessment of Maternal Blood Gas Changes When Using Atosiban and Terbutaline as Tocolytic Agents, During in Utero Repair of Myelomeningocele</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo General Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Myelomeningocele is a malformation with high incidence, and it consists in a neural tube
      defect. Fetal intrauterine surgery is an alternative for correction, and it improves the
      prognosis of the fetus, but has an increased risk of maternal complications and premature
      labor, as it can occur due to uterine stimulation. It is therefore essential that tocolysis
      is performed before, during and after surgery, and the most commonly used tocolytics are
      terbutaline and atosiban. Terbutaline has no specificity and may have several adverse effects
      such as maternal acidosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of the study was to evaluate maternal blood gas alterations among cases that
      use atosiban tocolytic agent and cases with terbutaline in in utero repair of
      myelomeningocele. It consists of a prospective, randomized, clinical, analytical study,
      covered for appraisers. It will include 28 patients, who will be divided into two groups that
      will receive two different tocolytics. The first group will receive terbutaline, and the
      second group will receive atosiban. The primary variable to be assessed will be maternal
      arterial pH at the end of surgery.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 8, 2017</start_date>
  <completion_date type="Anticipated">January 8, 2021</completion_date>
  <primary_completion_date type="Actual">April 19, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>It is a prospective randomized clinical, analytical study covered for appraisers. It will include 28 patients scheduled for in utero repair of myelomeningocele, to be divided into two groups. The first group will receive terbutaline for tocolysis, and the second group will receive atosiban. The primary dependent variable to be evaluated will be maternal arterial pH at the end of surgery. The changes in pH in maternal arterial blood gases will be compared between the two groups.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maternal arterial blood pH at the start of surgery</measure>
    <time_frame>Right after intubation</time_frame>
    <description>Arterial blood pH</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maternal arterial blood pH at the end of surgery</measure>
    <time_frame>Before extubation</time_frame>
    <description>Arterial blood pH</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maternal arterial blood pH at 120 minutes after surgery</measure>
    <time_frame>Two hours after the end of surgery</time_frame>
    <description>Arterial blood pH</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Short-term fetal repercussions</measure>
    <time_frame>In the end of the surgery, before extubation</time_frame>
    <description>Fetal heart rate in the immediate postoperative period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term fetal repercussions</measure>
    <time_frame>At the birth</time_frame>
    <description>Gestational age at birth</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Myelomeningocele</condition>
  <condition>Terbutaline Adverse Reaction</condition>
  <condition>Pregnancy; Malformation Central Nervous System</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous Atosiban.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous Terbutaline.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atosiban</intervention_name>
    <description>Atosiban intravenous. Dose: attack of 6.75 mg, and maintenance of 300 mcg / min for 3 hours, and 100 mcg / min for 45 h.</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Terbutaline</intervention_name>
    <description>Terbutaline intravenous. Dose: 2.5 mg in 500 mL saline, infusion rate of 30 mL / hr (150 mcg / hr) during the surgery</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnant women over 18 years

          -  Single fetus pregnancy

          -  Fetus with myelomeningocele

          -  Gestational age from 19 to 26

          -  Fetus with normal karyotype

        Exclusion Criteria:

          -  Multiple pregnancy

          -  Fetal abnormality not related to myelomeningocele

          -  Kyphosis greater than or equal to 30 degrees

          -  Placenta previa

          -  Maternal disease that increases the risk of pregnancy (insulin-dependent DM,
             hypertension poorly controlled)

          -  History of incompetent cervix

          -  Carrier of HIV, hepatitis B or hepatitis C

          -  Maternal-fetal isoimmunization

          -  Uterine Alteration

          -  Obesity (IMC greater than 30)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elaine I Moura, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital das Clinicas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hermann S Fernandes, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital das Clinicas</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elaine I Moura, MD</last_name>
    <phone>+5511981351412</phone>
    <email>elaineimaeda@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Faculdade de Medicina da Universidade de São Paulo</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hermann Fernandes</last_name>
      <phone>+5584988966348</phone>
      <email>hermann.fernandes@hc.fm.usp.br</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <results_reference>
    <citation>Ferschl M, Ball R, Lee H, Rollins MD. Anesthesia for in utero repair of myelomeningocele. Anesthesiology. 2013 May;118(5):1211-23. doi: 10.1097/ALN.0b013e31828ea597.</citation>
    <PMID>23508219</PMID>
  </results_reference>
  <results_reference>
    <citation>Boulet SL, Yang Q, Mai C, Kirby RS, Collins JS, Robbins JM, Meyer R, Canfield MA, Mulinare J; National Birth Defects Prevention Network. Trends in the postfortification prevalence of spina bifida and anencephaly in the United States. Birth Defects Res A Clin Mol Teratol. 2008 Jul;82(7):527-32. doi: 10.1002/bdra.20468.</citation>
    <PMID>18481813</PMID>
  </results_reference>
  <results_reference>
    <citation>Fichter MA, Dornseifer U, Henke J, Schneider KT, Kovacs L, Biemer E, Bruner J, Adzick NS, Harrison MR, Papadopulos NA. Fetal spina bifida repair--current trends and prospects of intrauterine neurosurgery. Fetal Diagn Ther. 2008;23(4):271-86. doi: 10.1159/000123614. Epub 2008 Apr 14. Review.</citation>
    <PMID>18417993</PMID>
  </results_reference>
  <results_reference>
    <citation>Adzick NS, Thom EA, Spong CY, Brock JW 3rd, Burrows PK, Johnson MP, Howell LJ, Farrell JA, Dabrowiak ME, Sutton LN, Gupta N, Tulipan NB, D'Alton ME, Farmer DL; MOMS Investigators. A randomized trial of prenatal versus postnatal repair of myelomeningocele. N Engl J Med. 2011 Mar 17;364(11):993-1004. doi: 10.1056/NEJMoa1014379. Epub 2011 Feb 9.</citation>
    <PMID>21306277</PMID>
  </results_reference>
  <results_reference>
    <citation>Fisk NM, Gitau R, Teixeira JM, Giannakoulopoulos X, Cameron AD, Glover VA. Effect of direct fetal opioid analgesia on fetal hormonal and hemodynamic stress response to intrauterine needling. Anesthesiology. 2001 Oct;95(4):828-35.</citation>
    <PMID>11605920</PMID>
  </results_reference>
  <results_reference>
    <citation>Cauldwell CB. Anesthesia for fetal surgery. Anesthesiol Clin North Am. 2002 Mar;20(1):211-26.</citation>
    <PMID>11892506</PMID>
  </results_reference>
  <results_reference>
    <citation>Devoto JC, Alcalde JL, Otayza F, Sepulveda W. Anesthesia for myelomeningocele surgery in fetus. Childs Nerv Syst. 2017 Jul;33(7):1169-1175. doi: 10.1007/s00381-017-3437-7. Epub 2017 May 25. Review.</citation>
    <PMID>28547209</PMID>
  </results_reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 1, 2020</study_first_submitted>
  <study_first_submitted_qc>July 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2020</study_first_posted>
  <last_update_submitted>July 10, 2020</last_update_submitted>
  <last_update_submitted_qc>July 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo General Hospital</investigator_affiliation>
    <investigator_full_name>Hermann dos Santos Fernandes</investigator_full_name>
    <investigator_title>Attending Anesthetist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningomyelocele</mesh_term>
    <mesh_term>Spina Bifida Cystica</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Terbutaline</mesh_term>
    <mesh_term>Atosiban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The IPD sharing plan includes informations about the demographic sample, the results of the study and the statistical analysis</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>From january/2020 until january/2022</ipd_time_frame>
    <ipd_access_criteria>Contact through email</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

